Use of aortic valve allografts from hepatitis B surface antigen-positive donors

11Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Over a 28-month period, 31 patients undergoing aortic valve replacement received valve allografts from hepatitis B surface antigen-positive, hepatitis B e antigen-negative donors. At the time of operation, 22 recipients were immune to hepatitis B infection; 19 had antibodies to hepatitis B surface antigen, and 3 were hepatitis B surface antigen positive. Nine patients were regarded as being susceptible to hepatitis B; 7 lacked hepatitis B markers, and records of serological status could not be found for the other 2. Four of the susceptible patients received hepatitis B immunoglobulin postoperatively, and 1 of them also received one 10-μg dose of hepatitis B vaccine. The 9 susceptible patients underwent hepatitis B serological studies a mean of 17 months (range, 4 to 31 months) postoperatively. In only 1 patient, tested 29 months after operation, had antibodies to hepatitis B surface, hepatitis B core, and hepatitis B e antigens developed. He had not experienced a clinical episode of hepatitis, and results of liver function tests were normal. He had not received prophylaxis. Because hepatitis B virus may be transmitted by hepatitis B surface antigen-positive, hepatitis B e antigen-negative valves, prophylaxis should be given whenever they are used and follow-up serological studies undertaken. © 1990.

Cite

CITATION STYLE

APA

Morris, A., Strickett, M. G., & Barratt-Boyes, B. G. (1990). Use of aortic valve allografts from hepatitis B surface antigen-positive donors. The Annals of Thoracic Surgery, 49(5), 802–805. https://doi.org/10.1016/0003-4975(90)90027-4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free